

## **ASX: EIQ RELEASE**

1 June 2023

## APPOINTMENT OF SIMON TOLHURST AS NON-EXECUTIVE DIRECTOR

**Sydney:** Al and Medical Technology company Echo IQ ("the Company" or "Echo IQ") (ASX:EIQ) is pleased to announce the appointment of Simon Tolhurst as a Non-Executive Director, effective from 1 June 2023.

Mr Tolhurst brings extensive board experience to the role. For five years, he was Non-Executive Chairman of ASX-listed NextEd Group Ltd (ASX:NXD) (formerly iCollege Limited) where he oversaw a period of significant growth, a company transformational acquisition matched with share price appreciation. He continues to serve as a Non-Executive Director at NextED Group Ltd (ASX:NXD) and holds other senior board roles in the private sector.

Simon has more than 30 years' experience in legal practice, and was until recently a Partner at HWL Ebsworth's Litigation Team prior to his recent retirement as a practicing lawyer. His areas of expertise include dispute resolution and competition law. He was named in *The Australian Financial Review*'s Best Lawyers® in the Litigation category, was recognised in Doyle's Guide as a Leading Commercial Litigation & Dispute Resolution Lawyer and was part of the HWL Ebsworth's National Competition Law and Anti-Trust Group that was recognised as a leading firm by both Chambers and Legal 500.

**Simon Tolhurst said**: "I am pleased to be joining Echo IQ at such a pivotal time in the Company's growth. With my focus as a professional company director, I am looking forward to supporting my fellow directors and the executive team as Echo IQ enters this critical expansion phase. As the company advances into new markets, most notably the United States, significant opportunities for new commercial and strategic partnerships are presenting themselves. I look forward to advising the company on how best to structure these opportunities for optimal delivery of long-term shareholder value."

**Echo IQ Chair Andrew Grover added**: "Simon's skill set are the ideal complement to the existing board members, and we are thrilled to welcome him as a Non-Executive Director. His extensive legal experience as well as his commercial acumen and strong track record as a Company Director will add significant value as Echo IQ aggressively pursues its growth objectives. We look forward to working with him."



ECHOIQ Limited ABN: 48 142 901 353 +61 2 9159 3719 / www.echoiq.ai 404/309 George Street, Sydney NSW 2000 Australia Subject to shareholder approval, the Company has agreed to issue 5,000,000 unlisted options in the capital of the Company exercisable at \$0.25 within 3 years of the date of issue to Mr Tolhurst or his nominee. The options are subject to a vesting condition of the provision of 6 months continuous service to the Company. The Company also confirms that Mr Tolhurst will be paid an annual non-executive director fee of \$66,000 per annum plus GST which will be paid from the shareholder approved non-executive director fee pool.

## - ENDS -

## Authorised for release by the Board of Directors of Echo IQ Limited.

Media Enquiries: Philip Woolff, Chief Operating Officer philip.woolff@echoiq.ai / +61 (0)490 030 620

Investor Enquiries: Andrew Grover, Executive Chair Andrew.grover@echoiq.ai / investor@echoiq.ai

ABOUT ECHO IQ

Echo IQ uses Al-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.



ECHOIQ Limited ABN: 48 142 901 353 +61 2 9159 3719 / www.echoiq.ai 404/309 George Street, Sydney NSW 2000 Australia